上海誼眾(688091.SH):與百洋醫藥簽訂市場推廣服務協議
格隆匯2月13日丨上海誼眾(688091.SH)公佈,公司在以自主營銷為主的營銷模式下,與百洋醫藥於近日就注射用紫杉醇聚合物膠束在自營以外指定區域的推廣達成合作共識並簽訂了《市場推廣服務協議》,該合作模式將成為對公司現有營銷模式的重要補充。
協議的簽訂有利於公司迅速形成銷售能力,加快市場滲透,提升盈利能力,預計對公司本年度及未來年度經營業績產生積極影響。
該協議指定合作推廣產品“注射用紫杉醇聚合物膠束”為公司核心產品,是國家藥品監督管理局批准的首個境內外均未上市的紫杉醇膠束類產品,屬於國家2.2類新藥、國家重大新藥創制項目。百洋醫藥為中國領先的健康品牌商業化平台,業務領域涵蓋全球優質醫藥健康品牌運營、批發配送和零售。百洋醫藥已合作大中型醫院1.4萬餘家、藥店36萬餘家。公司通過與百洋醫藥的推廣合作,有利於公司迅速形成銷售能力,加快市場滲透,提升盈利能力。公司堅持落實以自主營銷為主的營銷模式並持續探索創新營銷模式,此次與百洋醫藥形成的市場推廣合作模式將成為對公司現有營銷模式的重要補充。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.